ATE294572T1 - Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten - Google Patents

Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten

Info

Publication number
ATE294572T1
ATE294572T1 AT00986449T AT00986449T ATE294572T1 AT E294572 T1 ATE294572 T1 AT E294572T1 AT 00986449 T AT00986449 T AT 00986449T AT 00986449 T AT00986449 T AT 00986449T AT E294572 T1 ATE294572 T1 AT E294572T1
Authority
AT
Austria
Prior art keywords
medicament
create
treatment
gepirone
neurological diseases
Prior art date
Application number
AT00986449T
Other languages
English (en)
Inventor
Stephen J Kramer
Louis F Fabre
Joseph P Yevich
Original Assignee
Fabre Kramer Pharmaceuticals I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Kramer Pharmaceuticals I filed Critical Fabre Kramer Pharmaceuticals I
Application granted granted Critical
Publication of ATE294572T1 publication Critical patent/ATE294572T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00986449T 1999-12-20 2000-12-18 Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten ATE294572T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17268499P 1999-12-20 1999-12-20
US09/709,741 US6534507B1 (en) 1999-12-20 2000-11-13 Methods for treating psychological disorders using bioactive metabolites of gepirone
PCT/US2000/034131 WO2001045687A2 (en) 1999-12-20 2000-12-18 Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Publications (1)

Publication Number Publication Date
ATE294572T1 true ATE294572T1 (de) 2005-05-15

Family

ID=26868346

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986449T ATE294572T1 (de) 1999-12-20 2000-12-18 Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten

Country Status (20)

Country Link
US (1) US6534507B1 (de)
EP (1) EP1242061B1 (de)
JP (1) JP4236407B2 (de)
KR (1) KR100602976B1 (de)
CN (1) CN1411375A (de)
AT (1) ATE294572T1 (de)
AU (1) AU776409B2 (de)
CA (1) CA2395458C (de)
CZ (1) CZ300429B6 (de)
DE (1) DE60019968T2 (de)
ES (1) ES2241683T3 (de)
HU (1) HU228963B1 (de)
IL (2) IL150222A0 (de)
MX (1) MXPA02006146A (de)
NO (1) NO323304B1 (de)
NZ (1) NZ519554A (de)
PL (1) PL200378B1 (de)
PT (1) PT1242061E (de)
RU (1) RU2282448C2 (de)
WO (1) WO2001045687A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295478A1 (en) * 2000-08-22 2002-03-04 Akzo Nobel N.V. Active metabolite of gepirone
US20040000689A1 (en) * 2002-06-28 2004-01-01 Erh-Kun Lai Dual-bit MONOS/SONOS memory structure with non-continuous floating gate
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
WO2004014309A2 (en) * 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Improved process for hydroxyazapirones
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
TW200521125A (en) * 2003-11-18 2005-07-01 Bristol Myers Squibb Co Continuous process for producing hydroxyazapirones by oxidation
WO2006052227A1 (en) * 2004-11-05 2006-05-18 Fabre-Kramer Holdings, Inc. High-dosage extended-release formulation of gepirone
CN102026639A (zh) * 2008-05-08 2011-04-20 法布雷－克雷默医药公司 用于治疗注意力缺陷障碍和性功能障碍的3-羟基吉哌隆

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5185329A (en) * 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
DE60019968T2 (de) 2006-02-02
CA2395458C (en) 2009-05-12
HUP0301831A2 (hu) 2003-09-29
CZ20022137A3 (cs) 2003-03-12
NO20022954D0 (no) 2002-06-19
EP1242061A2 (de) 2002-09-25
DE60019968D1 (de) 2005-06-09
IL150222A (en) 2009-09-22
PL200378B1 (pl) 2008-12-31
PT1242061E (pt) 2005-09-30
RU2282448C2 (ru) 2006-08-27
KR100602976B1 (ko) 2006-07-20
CZ300429B6 (cs) 2009-05-20
IL150222A0 (en) 2002-12-01
AU776409B2 (en) 2004-09-09
WO2001045687A2 (en) 2001-06-28
JP4236407B2 (ja) 2009-03-11
RU2002119400A (ru) 2004-01-27
AU2268701A (en) 2001-07-03
ES2241683T3 (es) 2005-11-01
EP1242061B1 (de) 2005-05-04
NZ519554A (en) 2005-01-28
MXPA02006146A (es) 2004-08-23
NO20022954L (no) 2002-06-19
KR20020082470A (ko) 2002-10-31
NO323304B1 (no) 2007-03-05
US6534507B1 (en) 2003-03-18
CN1411375A (zh) 2003-04-16
CA2395458A1 (en) 2001-06-28
JP2004500362A (ja) 2004-01-08
WO2001045687A3 (en) 2002-04-25
PL364936A1 (en) 2004-12-27
HU228963B1 (en) 2013-07-29

Similar Documents

Publication Publication Date Title
AU711212B2 (en) Methods for treating allergic disorders using (-) cetirizine
ES2257757T3 (es) Carboxilato de terfenadina y el tratamiento de trastornos alergicos.
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2001517639A (ja) 鼻炎／結膜炎および感冒、感冒に似た症状および／または流行性感冒の症状を局所的に治療するための、鎮静作用を有しない抗ヒスタミンおよびα−アドレナリン作動薬を含む組合せ物の使用
BRPI0618239A2 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusico
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
CN102647986A (zh) 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法
US5627183A (en) Methods for treating urticaria using optically pure (+) cetirizine
DE60019968D1 (de) Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten
BR0308982A (pt) Combinações de epinastina, beladona e pseudoefedrina como novas formulações farmacêuticas
ATE460933T1 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
CA2364178A1 (en) N-benzenesulfonyl l-proline compounds as bradykinin antagonists
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
RU2004126447A (ru) Лечение ревматоидного артрита
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
RU2004112422A (ru) Роувастатин в преддеменционных состояниях
SE0102887D0 (sv) New formulation
FR2696741B1 (fr) Dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl]piperidin-1-yl] éthanol, leur préparation et leur application en thérapeutique.
AU2005205914A1 (en) Combination of organic compounds
RU2005140516A (ru) Применение ингибитора тирозинкиназы для лечения диабета
AU703690B2 (en) Methods for treating allergic disorders using optically pure (+)cetirizine
WO2004050019A3 (en) Method and compositions for treating anxiety

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242061

Country of ref document: EP